Seelos Therapeutics, Inc. (SEEL)
Company Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders.
The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).
Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012.
The company was founded in 2016 and is headquartered in New York, New York.
Country | United States |
Founded | 2016 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 15 |
CEO | Dr. Raj Mehra J.D., Ph.D. |
Contact Details
Address: 300 Park Avenue, 2nd Floor New York, New York 10022 United States | |
Phone | (646) 293-2100 |
Website | seelostherapeutics.com |
Stock Details
Ticker Symbol | SEEL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001017491 |
CUSIP Number | 81577F109 |
ISIN Number | US81577F2083 |
Employer ID | 87-0449967 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Raj Mehra J.D., Ph.D. | Founder, Chairman, Chief Executive Officer and President |
Michael J. Golembiewski | Chief Financial Officer |
Kimberly Farrand | Senior Director of Clinical Development and Operations |
Anthony Marciano | Chief Communications Officer |
Gopal Krishna Ph.D. | Head of Manufacturing and Technical Operations |
Tim Whitaker M.D. | Chief Medical Officer |
Karen Fusaro | Senior Vice President and Head of Clinical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 19, 2024 | 8-K | Current Report |
Mar 15, 2024 | EFFECT | Notice of Effectiveness |
Mar 15, 2024 | 424B3 | Prospectus |
Mar 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 6, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Mar 6, 2024 | 10-K | Annual Report |
Feb 14, 2024 | D | Notice of Exempt Offering of Securities |
Feb 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 2, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Jan 30, 2024 | 8-K | Current Report |